Markets
Will any new lung health breakthrough be published in a peer-reviewed journal by December 31, 2026?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if a new lung health breakthrough, funded by the American Lung Association, is published in a peer-reviewed journal by December 31, 2026. The breakthrough must be a significant advancement or discovery in lung health fields such as lung cancer, asthma, COPD, or other respiratory threats.
Rules
- Market closes at 12/31/2026.
- Logic weighted resolution applies.
Other open markets in Health
Will the da Vinci 5 system be deployed in at least 500 additional hospitals worldwide by December 31, 2027?
This market resolves to Yes if publicly verifiable reports or official announcements confirm that the da Vinci 5 robotic surgical system has been deployed in at least 500 additional hospitals worldwide by December 31, 2027. The count will include hospitals that adopt the system for the first time or upgrade from older models to the da Vinci 5. Deployment must be substantiated by Intuitive Surgical (the manufacturer), validated press releases, or other credible sources by the resolution date.
Will any U.S. hospital perform a fully remote robotic surgery with the da Vinci 5 system by January 31, 2027?
This market resolves to Yes if any U.S. hospital performs a fully remote (surgeon operating from a physically separate location) robotic surgery using the da Vinci 5 system by January 31, 2027. Verification will depend on public announcements, press releases, or trusted reporting from reputable medical or news organizations.
Will the FDA approve an AI-based clinical trial consent form translation tool by March 31, 2027?
This market resolves to Yes if the FDA officially approves any AI-based tool for translating clinical trial consent forms by March 31, 2027. Approval must be publicly announced by the FDA or the tool's developers, and explicitly described as intended for use in translating clinical trial consent forms.
Will the new dual-drug strategy for triple-negative breast cancer show a significant improvement in patient outcomes by March 2027?
This market resolves to Yes if peer-reviewed study results published by March 2027 show that the dual-drug strategy significantly improves clinical outcomes (such as progression-free survival or overall response rate) for patients with triple-negative breast cancer compared to current standard treatments.
Will the proposed combination of Atrium and WakeMed be approved by February 2027?
This market resolves to Yes if the proposed combination of healthcare providers Atrium and WakeMed receives approval from the relevant regulatory authorities by February 2027. The approval must be publicly confirmed by that date.
Will the US National Institutes of Health introduce new guidelines for exercise in older adults by December 31, 2026?
This market resolves to Yes if the US National Institutes of Health (NIH) publicly announces new guidelines specifically aimed at exercise for adults aged 65 and older by December 31, 2026. The announcement must be reported by a credible health or governmental news source.